available only through 503A compounding pharmacies under physician supervision Typical research dose range / 200-800 mcg/day subcutaneously, cycled 4-8 weeks Known lethal dose (LD50) / Not established in any species studied to date Rodent acute toxicity ceiling / No mortality observed at doses exceeding 10 mg/kg intraperitoneally Most reported excess-dose symptoms / Nausea, lightheadedness, flushing, injection-site irritation Organ toxicity at supratherapeutic doses / Not demonstrated in published preclinical literature Antidote availability / No specific antidote exists
Some doctors in the integrative and regenerative medicine community believe they are miracle substances
Already in effect (January 1, 2026): Standard PA decisions within 7 calendar days (down from 14) Urgent PA decisions within 72 hours Specific denial reasons required on every denial (not just not medically necessary) Applies to Medicare Advantage, Medicaid managed care, CHIP, and ACA Marketplace plans Coming March 31, 2026: Payers must publicly report PA metrics for calendar year 2025: approval/denial rates, average decision times, and appeals outcomes Providers will be able to compare payer performance for the first time Coming January 1, 2027: FHIR-based Prior Authorization APIs required providers check PA requirements, submit requests, and receive decisions electronically through their EHR Expected to reduce average PA processing time from days to minutes for standard requests Medicare WISeR Model (live in AZ and WA): The Wasteful and Inappropriate Services Reduction pilot launched January 2026 in six states including Arizona and Washington
BPC-157 , 15
No side effects, lost about 6lbs in 4 weeks
